Market Cap | 13.13K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -5.15M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -12.00% |
Sales | 7.38k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -94.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -99.00% |
Recommedations | - | Quick Ratio | - | Shares Outstanding | 131.29M | 52W Low Chg | - |
Insider Own | 10.31% | ROA | -1,194.28% | Shares Float | 118.94M | Beta | -11.75 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 9,200 | Target Price | - |
Oper. Margin | -56,754.27% | Earnings Date | - | Volume | 32 | Change | 0.00% |
Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.